-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30.
-
(2006)
CA Cancer J Clin
, vol.56
, Issue.2
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Smigal, C.6
-
2
-
-
0000368040
-
Intermittent androgen suppression for prostate cancer:rationale and clinical experience
-
Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer:rationale and clinical experience. Prostate Cancer Prostatic Dis. 1998;1(6):289-96.
-
(1998)
Prostate Cancer Prostatic Dis
, vol.1
, Issue.6
, pp. 289-296
-
-
Gleave, M.1
Goldenberg, S.L.2
Bruchovsky, N.3
Rennie, P.4
-
3
-
-
0032497522
-
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
-
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-42.
-
(1998)
N Engl J Med
, vol.339
, Issue.15
, pp. 1036-1042
-
-
Eisenberger, M.A.1
Blumenstein, B.A.2
Crawford, E.D.3
Miller, G.4
McLeod, D.G.5
Loehrer, P.J.6
-
4
-
-
58949101975
-
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors
-
Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res. 2009;15(1):39-47.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.1
, pp. 39-47
-
-
Snoek, R.1
Cheng, H.2
Margiotti, K.3
Wafa, L.A.4
Wong, C.A.5
Wong, E.C.6
-
5
-
-
0035496220
-
The development of androgenindependent prostate cancer
-
Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001;1(1):34-45.
-
(2001)
Nat Rev Cancer
, vol.1
, Issue.1
, pp. 34-45
-
-
Feldman, B.J.1
Feldman, D.2
-
6
-
-
4944246790
-
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
-
Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11(3):459-76.
-
(2004)
Endocr Relat Cancer
, vol.11
, Issue.3
, pp. 459-476
-
-
Scher, H.I.1
Buchanan, G.2
Gerald, W.3
Butler, L.M.4
Tilley, W.D.5
-
7
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
-
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375[9724]:1437-46.
-
(2010)
Lancet
, vol.375
, Issue.9724
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
Anand, A.4
Taplin, M.E.5
Efstathiou, E.6
-
8
-
-
84877686260
-
A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo
-
Epub 2013/03/16
-
Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Molecular cancer therapeutics. 2013;12(5):567-76. Epub 2013/03/16.
-
(2013)
Molecular cancer therapeutics
, vol.12
, Issue.5
, pp. 567-576
-
-
Kuruma, H.1
Matsumoto, H.2
Shiota, M.3
Bishop, J.4
Lamoureux, F.5
Thomas, C.6
-
9
-
-
65549168746
-
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
-
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305-13.
-
(2009)
Cancer Res
, vol.69
, Issue.6
, pp. 2305-2313
-
-
Guo, Z.1
Yang, X.2
Sun, F.3
Jiang, R.4
Linn, D.E.5
Chen, H.6
-
10
-
-
79960979238
-
-
Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol. 2011.
-
(2011)
J Mol Endocrinol
-
-
Shiota, M.1
Yokomizo, A.2
Naito, S.3
-
11
-
-
77955296562
-
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
-
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715-30.
-
(2010)
J Clin Invest
, vol.120
, Issue.8
, pp. 2715-2730
-
-
Sun, S.1
Sprenger, C.C.2
Vessella, R.L.3
Haugk, K.4
Soriano, K.5
Mostaghel, E.A.6
-
12
-
-
51049098138
-
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castrationresistant prostate cancer
-
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castrationresistant prostate cancer. Cancer Res. 2008;68(15):6407-15.
-
(2008)
Cancer Res
, vol.68
, Issue.15
, pp. 6407-6415
-
-
Locke, J.A.1
Guns, E.S.2
Lubik, A.A.3
Adomat, H.H.4
Hendy, S.C.5
Wood, C.A.6
-
13
-
-
1342325380
-
Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer
-
Epub 2003/12/10
-
Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem. 2004;279(8):7119-30. Epub 2003/12/10.
-
(2004)
J Biol Chem
, vol.279
, Issue.8
, pp. 7119-7130
-
-
Gregory, C.W.1
Fei, X.2
Ponguta, L.A.3
He, B.4
Bill, H.M.5
French, F.S.6
-
14
-
-
16344363218
-
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth
-
Epub 2005/03/10
-
Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005;11(5):1704-12. Epub 2005/03/10.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.5
, pp. 1704-1712
-
-
Gregory, C.W.1
Whang, Y.E.2
McCall, W.3
Fei, X.4
Liu, Y.5
Ponguta, L.A.6
-
15
-
-
7944234374
-
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability
-
Epub 2004/11/16
-
Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6(5):517-27. Epub 2004/11/16.
-
(2004)
Cancer Cell
, vol.6
, Issue.5
, pp. 517-527
-
-
Mellinghoff, I.K.1
Vivanco, I.2
Kwon, A.3
Tran, C.4
Wongvipat, J.5
Sawyers, C.L.6
-
16
-
-
0036847724
-
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
-
Epub 2002/11/14
-
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8(11):3438-44. Epub 2002/11/14.
-
(2002)
Clin Cancer Res
, vol.8
, Issue.11
, pp. 3438-3444
-
-
Di Lorenzo, G.1
Tortora, G.2
D'Armiento, F.P.3
De Rosa, G.4
Staibano, S.5
Autorino, R.6
-
17
-
-
84869071866
-
Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors
-
Epub 2012/12/21
-
Carlsson J, Shen L, Xiang J, Xu J, Wei Q. Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncology letters. 2013;5(1):208-14. Epub 2012/12/21.
-
(2013)
Oncology letters
, vol.5
, Issue.1
, pp. 208-214
-
-
Carlsson, J.1
Shen, L.2
Xiang, J.3
Xu, J.4
Wei, Q.5
-
18
-
-
0037105743
-
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts
-
Epub 2002/09/18
-
Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 2002;62(18):5254-9. Epub 2002/09/18.
-
(2002)
Cancer Res
, vol.62
, Issue.18
, pp. 5254-5259
-
-
Mellinghoff, I.K.1
Tran, C.2
Sawyers, C.L.3
-
19
-
-
17144400795
-
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer
-
Epub 2005/04/19
-
Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005;65(8):3404-9. Epub 2005/04/19.
-
(2005)
Cancer Res
, vol.65
, Issue.8
, pp. 3404-3409
-
-
Liu, Y.1
Majumder, S.2
McCall, W.3
Sartor, C.I.4
Mohler, J.L.5
Gregory, C.W.6
-
20
-
-
69349097177
-
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer
-
Epub 2009/04/14
-
Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, et al. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol. 2009;32(4):338-41. Epub 2009/04/14.
-
(2009)
Am J Clin Oncol
, vol.32
, Issue.4
, pp. 338-341
-
-
Pezaro, C.1
Rosenthal, M.A.2
Gurney, H.3
Davis, I.D.4
Underhill, C.5
Boyer, M.J.6
-
21
-
-
82555199456
-
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
-
Epub 2011/03/15
-
Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, et al. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. 2011. Epub 2011/03/15.
-
(2011)
Urol Oncol
-
-
Whang, Y.E.1
Armstrong, A.J.2
Rathmell, W.K.3
Godley, P.A.4
Kim, W.Y.5
Pruthi, R.S.6
-
22
-
-
79955975429
-
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
-
Epub 2011/05/18
-
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-86. Epub 2011/05/18.
-
(2011)
Cancer Cell
, vol.19
, Issue.5
, pp. 575-586
-
-
Carver, B.S.1
Chapinski, C.2
Wongvipat, J.3
Hieronymus, H.4
Chen, Y.5
Chandarlapaty, S.6
-
23
-
-
33645218804
-
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species
-
Epub 2005/12/16
-
Evdokimova V, Ruzanov P, Anglesio MS, Sorokin AV, Ovchinnikov LP, Buckley J, et al. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol. 2006;26(1):277-92. Epub 2005/12/16.
-
(2006)
Mol Cell Biol
, vol.26
, Issue.1
, pp. 277-292
-
-
Evdokimova, V.1
Ruzanov, P.2
Anglesio, M.S.3
Sorokin, A.V.4
Ovchinnikov, L.P.5
Buckley, J.6
-
24
-
-
78649869697
-
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1
-
Epub 2010/09/15
-
Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, et al. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene. 2010;29(48):6343-56. Epub 2010/09/15.
-
(2010)
Oncogene
, vol.29
, Issue.48
, pp. 6343-6356
-
-
Kalra, J.1
Sutherland, B.W.2
Stratford, A.L.3
Dragowska, W.4
Gelmon, K.A.5
Dedhar, S.6
-
25
-
-
33646394318
-
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2
-
Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66(9):4872-9.
-
(2006)
Cancer Res
, vol.66
, Issue.9
, pp. 4872-4879
-
-
Wu, J.1
Lee, C.2
Yokom, D.3
Jiang, H.4
Cheang, M.C.5
Yorida, E.6
-
26
-
-
0033022342
-
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase
-
Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase. Nat Med. 1999;5(3):280-5.
-
(1999)
Nat Med
, vol.5
, Issue.3
, pp. 280-285
-
-
Craft, N.1
Shostak, Y.2
Carey, M.3
Sawyers, C.L.4
-
27
-
-
34347263425
-
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
-
Epub 2007/05/15
-
Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A. 2007;104(20):8438-43. Epub 2007/05/15.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, Issue.20
, pp. 8438-8443
-
-
Mahajan, N.P.1
Liu, Y.2
Majumder, S.3
Warren, M.R.4
Parker, C.E.5
Mohler, J.L.6
-
28
-
-
84929025574
-
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
-
Epub 2014/08/26
-
Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, et al. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. European urology. 2014. Epub 2014/08/26.
-
(2014)
European urology
-
-
Toren, P.1
Kim, S.2
Cordonnier, T.3
Crafter, C.4
Davies, B.R.5
Fazli, L.6
-
29
-
-
35948978956
-
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
-
Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer. 2007;14(3):601-11.
-
(2007)
Endocr Relat Cancer
, vol.14
, Issue.3
, pp. 601-611
-
-
Festuccia, C.1
Gravina, G.L.2
Muzi, P.3
Pomante, R.4
Ventura, L.5
Vessella, R.L.6
-
30
-
-
44849135655
-
Epidermal growth factor receptor [EGFR] expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis
-
Marks RA, Zhang S, Montironi R, McCarthy RP, MacLennan GT, Lopez-Beltran A, et al. Epidermal growth factor receptor [EGFR] expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate. 2008;68(9):919-23.
-
(2008)
Prostate
, vol.68
, Issue.9
, pp. 919-923
-
-
Marks, R.A.1
Zhang, S.2
Montironi, R.3
McCarthy, R.P.4
MacLennan, G.T.5
Lopez-Beltran, A.6
-
31
-
-
77649108628
-
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer
-
Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010;16(5):1553-60.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.5
, pp. 1553-1560
-
-
Minner, S.1
Jessen, B.2
Stiedenroth, L.3
Burandt, E.4
Kollermann, J.5
Mirlacher, M.6
-
32
-
-
80053506738
-
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3
-
Epub 2011/08/17
-
Chen L, Mooso B, Jathal MK, Madhav A, Johnson SD, van Spyk E, et al. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011. Epub 2011/08/17.
-
(2011)
Clin Cancer Res
-
-
Chen, L.1
Mooso, B.2
Jathal, M.K.3
Madhav, A.4
Johnson, S.D.5
van Spyk, E.6
-
33
-
-
78650006394
-
A multicenter phase II clinical trial of lapatinib [GW572016] in hormonally untreated advanced prostate cancer
-
Epub 2010/01/01
-
Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib [GW572016] in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 2010;33(6):609-13. Epub 2010/01/01.
-
(2010)
Am J Clin Oncol
, vol.33
, Issue.6
, pp. 609-613
-
-
Sridhar, S.S.1
Hotte, S.J.2
Chin, J.L.3
Hudes, G.R.4
Gregg, R.5
Trachtenberg, J.6
-
34
-
-
40449092491
-
Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers
-
Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68(5):1504-12.
-
(2008)
Cancer Res
, vol.68
, Issue.5
, pp. 1504-1512
-
-
Fujii, T.1
Kawahara, A.2
Basaki, Y.3
Hattori, S.4
Nakashima, K.5
Nakano, K.6
-
35
-
-
69549091683
-
Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer
-
Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1066-74.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.9
, pp. 1066-1074
-
-
Kashihara, M.1
Azuma, K.2
Kawahara, A.3
Basaki, Y.4
Hattori, S.5
Yanagawa, T.6
-
36
-
-
80052065124
-
YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification
-
Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S, et al. YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene. 2011;30(34):3649-60.
-
(2011)
Oncogene
, vol.30
, Issue.34
, pp. 3649-3660
-
-
Davies, A.H.1
Barrett, I.2
Pambid, M.R.3
Hu, K.4
Stratford, A.L.5
Freeman, S.6
-
37
-
-
84882735079
-
Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability
-
Epub 2013/06/22
-
Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, et al. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Res. 2013;73(16):5206-17. Epub 2013/06/22.
-
(2013)
Cancer Res
, vol.73
, Issue.16
, pp. 5206-5217
-
-
Matsumoto, H.1
Yamamoto, Y.2
Shiota, M.3
Kuruma, H.4
Beraldi, E.5
Matsuyama, H.6
-
38
-
-
66149147100
-
Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth
-
Epub 2009/03/26
-
Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer research. 2009;69(7):3148-56. Epub 2009/03/26.
-
(2009)
Cancer research
, vol.69
, Issue.7
, pp. 3148-3156
-
-
Shiota, M.1
Izumi, H.2
Tanimoto, A.3
Takahashi, M.4
Miyamoto, N.5
Kashiwagi, E.6
-
39
-
-
84855577580
-
Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer
-
Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol. 2012;187(2):707-14.
-
(2012)
J Urol
, vol.187
, Issue.2
, pp. 707-714
-
-
Shiota, M.1
Song, Y.2
Takeuchi, A.3
Yokomizo, A.4
Kashiwagi, E.5
Kuroiwa, K.6
-
40
-
-
80052161751
-
Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression
-
Epub 2011/06/10
-
Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocrine-related cancer. 2011;18(4):505-17. Epub 2011/06/10.
-
(2011)
Endocrine-related cancer
, vol.18
, Issue.4
, pp. 505-517
-
-
Shiota, M.1
Takeuchi, A.2
Song, Y.3
Yokomizo, A.4
Kashiwagi, E.5
Uchiumi, T.6
-
41
-
-
84055182512
-
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer
-
Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res. 2011;9(12):1755-66.
-
(2011)
Mol Cancer Res
, vol.9
, Issue.12
, pp. 1755-1766
-
-
Shiota, M.1
Zoubeidi, A.2
Kumano, M.3
Beraldi, E.4
Naito, S.5
Nelson, C.C.6
-
42
-
-
84928722323
-
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
-
Epub 2014/11/28
-
Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2014. Epub 2014/11/28.
-
(2014)
Oncotarget
-
-
Bishop, J.L.1
Sio, A.2
Angeles, A.3
Roberts, M.E.4
Azad, A.A.5
Chi, K.N.6
-
43
-
-
33750324597
-
HER2/Neu [ErbB2] signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta
-
Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu [ErbB2] signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 2006;66(19):9591-600.
-
(2006)
Cancer Res
, vol.66
, Issue.19
, pp. 9591-9600
-
-
Wang, S.E.1
Shin, I.2
Wu, F.Y.3
Friedman, D.B.4
Arteaga, C.L.5
-
44
-
-
84922227588
-
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
-
Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, et al. Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. Mol Cancer Ther. 2014.
-
(2014)
Mol Cancer Ther
-
-
Toren, P.J.1
Kim, S.2
Pham, S.3
Mangalji, A.4
Adomat, H.5
Guns, E.S.6
-
45
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
-
Epub 1984/01/01
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55. Epub 1984/01/01.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
|